Novartis set to take on Roche as FDA clears first at-home, injectable MS drug

The Food and Drug Administration on Thursday approved Kesimpta, formerly known as ofatumumab, a drug developed by Novartis for patients with the relapsing form of multiple sclerosis, the most common form of the disease.